AC IMMUNE SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.65 USD | +17.42% |
|
+31.36% | -7.00% |
| May. 31 | BTIG Starts AC Immune With Buy Rating, $8 Price Target | MT |
| May. 13 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 590.5 | 351.1 | 423 | 145.7 | 415.5 | 394.7 | - | - |
| Enterprise Value (EV) 1 | 590.5 | 351.1 | 423 | 145.7 | 415.5 | 262.9 | 307.3 | 381.9 |
| P/E ratio | 12.9 x | -5.32 x | -4.65 x | -2.22 x | -6.57 x | -42.7 x | 14.8 x | -10.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.32 x | 22.8 x | - | 37 x | 28.1 x | 5.63 x | 3.37 x | 7.78 x |
| EV / Revenue | 5.32 x | 22.8 x | - | 37 x | 28.1 x | 3.75 x | 2.62 x | 7.53 x |
| EV / EBITDA | 12.9 x | -5.92 x | -5.52 x | -2.13 x | -8.08 x | 23.1 x | -5.96 x | -4.77 x |
| EV / FCF | - | -5.73 x | -6.19 x | -1.95 x | -6.79 x | -2.99 x | 12.1 x | 7.38 x |
| FCF Yield | - | -17.4% | -16.2% | -51.3% | -14.7% | -33.4% | 8.24% | 13.5% |
| Price to Book | 2.17 x | 1.53 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 71,662 | 76,741 | 93,691 | 77,257 | 98,801 | 93,954 | - | - |
| Reference price 2 | 8.240 | 4.575 | 4.515 | 1.886 | 4.205 | 4.201 | 4.201 | 4.201 |
| Announcement Date | 3/30/20 | 3/23/21 | 3/22/22 | 3/16/23 | 3/14/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 111 | 15.43 | - | 3.935 | 14.8 | 70.08 | 117.2 | 50.75 |
| EBITDA 1 | 45.81 | -59.29 | -76.6 | -68.49 | -51.41 | 11.4 | -51.6 | -80.1 |
| EBIT 1 | 44.54 | -61.26 | -79.01 | -70.85 | -53.62 | -21.81 | 25.02 | -37.41 |
| Operating Margin | 40.11% | -396.99% | - | -1,800.43% | -362.3% | -31.13% | 21.36% | -73.71% |
| Earnings before Tax (EBT) 1 | 45.44 | -61.92 | -72.99 | -70.74 | -54.22 | -19.75 | 26.06 | -36.48 |
| Net income 1 | 45.44 | -61.92 | -73 | -70.75 | -54.23 | -9.957 | 28.83 | -44.23 |
| Net margin | 40.93% | -401.28% | - | -1,798.04% | -366.41% | -14.21% | 24.6% | -87.16% |
| EPS 2 | 0.6400 | -0.8600 | -0.9700 | -0.8500 | -0.6400 | -0.0985 | 0.2845 | -0.4048 |
| Free Cash Flow 1 | - | -61.22 | -68.32 | -74.81 | -61.21 | -87.9 | 25.33 | 51.74 |
| FCF margin | - | -396.75% | - | -1,901.07% | -413.55% | -125.44% | 21.62% | 101.95% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | 87.88% | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/23/21 | 3/22/22 | 3/16/23 | 3/14/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 3.934 | 0.001 | - | - | - | 14.8 | - | 68.12 | 0.25 | 1.725 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -22.79 | -18.83 | -19.86 | -13.46 | -18.7 | -17.57 | -17.05 | -15.47 | -3.541 | -20.07 | 39.81 | -20.7 | -20.72 | - | - |
| Operating Margin | - | - | - | -342.22% | -1,869,500% | - | - | - | -23.92% | - | 58.44% | -8,278.48% | -1,201.43% | - | - |
| Earnings before Tax (EBT) 1 | -21.27 | -18.84 | -19.64 | -13.51 | -18.74 | -17.51 | -16.83 | -15.14 | -4.743 | -17.86 | 40.04 | -20.4 | -20.45 | - | - |
| Net income 1 | -21.28 | -18.85 | -19.64 | -13.52 | -18.75 | -17.51 | -16.83 | -15.14 | -4.744 | -17.86 | 47.85 | -20.22 | -18.91 | -21.29 | -21.8 |
| Net margin | - | - | - | -343.57% | -1,874,600% | - | - | - | -32.05% | - | 70.24% | -8,089.61% | -1,096.19% | - | - |
| EPS 2 | -0.2600 | -0.2300 | -0.2300 | -0.1600 | -0.2300 | -0.2100 | -0.2000 | -0.1800 | -0.0500 | -0.1800 | 0.4755 | -0.2020 | -0.1895 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/22/22 | 4/28/22 | 7/28/22 | 10/28/22 | 3/16/23 | 4/28/23 | 8/4/23 | 11/3/23 | 3/14/24 | 5/13/24 | - | - | - | - | - |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | - | 132 | 87.4 | 12.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -61.2 | -68.3 | -74.8 | -61.2 | -87.9 | 25.3 | 51.7 |
| ROE (net income / shareholders' equity) | 20.2% | -25.4% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 3.790 | 3.000 | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.89 | 1.71 | 2.64 | 1.24 | 0.8 | 1.41 | 1.58 | 1.65 |
| Capex / Sales | 1.7% | 11.06% | - | 31.49% | 5.41% | 2.02% | 1.35% | 3.25% |
| Announcement Date | 3/30/20 | 3/23/21 | 3/22/22 | 3/16/23 | 3/14/24 | - | - | - |
1CHF in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.201
CHF
Average target price
9.296
CHF
Spread / Average Target
+121.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.00% | 437M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- ACIU Stock
- Financials AC Immune SA
